This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Natus Medical (BABY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Natus Medical (BABY) delivered earnings and revenue surprises of 13.33% and 2.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Natus Medical (BABY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Natus Medical (BABY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natus Medical to Divest Medix for Focusing on Core Business
by Zacks Equity Research
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
New Strong Sell Stocks for February 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Natus Medical (BABY) Q4 Earnings Miss Estimates
by Zacks Equity Research
Natus Medical (BABY) delivered earnings and revenue surprises of -14.00% and 3.44%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Natus Medical (BABY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Natus Medical (BABY)
by Zacks Equity Research
Natus Medical Incorporated (BABY) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
ResMed's Out-of-Hospital Line to Grow With MatrixCare Buyout
by Zacks Equity Research
MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.
Natus Medical (BABY) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Natus Medical (BABY) delivered earnings and revenue surprises of -4.76% and -1.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Natus Medical (BABY) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tap the Sleep Apnea Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the sleep apnea devices market for grand returns.
Natus Medical (BABY) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Natus Medical (BABY) delivered earnings and revenue surprises of 34.62% and 0.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Natus Medical (BABY) is in Overbought Territory: What's Next?
by Zacks Equity Research
Natus Medical Incorporated (BABY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
What Falling Estimates & Price Mean for Natus Medical (BABY)
by Zacks Equity Research
It seems to be a wise decision for investors to drop Natus Medical (BABY) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
SMART Global Holdings, Natus Medical, Interactive Brokers Group, Renasant and GATX highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
SMART Global Holdings, Natus Medical, Interactive Brokers Group, Renasant and GATX highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Natus Medical (BABY)
by Kevin Cook
Specialty products for the care, diagnosis and treatment of newborn neurology are seeing a softer outlook for the new year
4 Growth Stocks to Pick From a Choppy MedTech Market
by Zacks Equity Research
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
Ekso Bionics (EKSO) in Focus: Stock Moves 6.6% Higher
by Kaibalya Pravo Dey
Ekso Bionics (EKSO) shares rose nearly 7% in the last trading session, amid huge volumes.
Zacks.com highlights: Natus Medical, GoPro, Enviva Partners and Bruker
by Zacks Equity Research
Zacks.com highlights: Natus Medical, GoPro, Enviva Partners and Bruker
4 Top Stocks With Earnings Acceleration to Buy Now
by Tirthankar Chakraborty
Studies have shown that a majority of stocks had seen acceleration in earnings before an uptick in the stock price.
Integra Closes Codman Buyout, Strengthens Neurosurgery Arm
by Zacks Equity Research
With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.
Integra Divests Assets to Natus, Paves Way for Codman Buyout
by Zacks Equity Research
Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.
Medical Instrument Stocks' Earnings on Feb 1: EW, HOLX, BABY
by Zacks Equity Research
Already more than one-third of the S&P 500 members (170 companies making up for 19.2% of the total market cap) have reported their Oct--Dec 2016 quarter's earnings results.
This Week's Hidden Gems: (BABY)(COHR)
by Tracey Ryniec
Tracey Ryniec uncovers two top stocks that are flying under the radar.